March 01, 2015 11:41 AM ET

Pharmaceuticals

Company Overview of Horizon Pharma plc

Company Overview

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA ...

Adelaide Chambers

Peter Street

Dublin,  8

Ireland

Founded in 2005

Phone:

353 1 649 8521

Key Executives for Horizon Pharma plc

Chairman, Chief Executive Officer and President
Age: 47
Total Annual Compensation: $589.2K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 59
Total Annual Compensation: $396.3K
Consultant
Age: 56
Total Annual Compensation: $374.9K
Compensation as of Fiscal Year 2013.

Horizon Pharma plc Key Developments

Horizon Pharma plc Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Revised Earnings Guidance for the Year 2015

Horizon Pharma plc announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s total net sales were $103.8 million, compared with $30.1 million in the fourth quarter of 2013, representing 245% year over year growth. Operating income was $8,983 million against operating loss of $5,762 million a year ago. Loss before benefit for income taxes was $34,464 million against $103,055 million a year ago. Net loss was $31,647 million against $102,901 million a year ago. Net loss per basic and diluted share was $0.27 against $1.56 a year ago. Adjusted non-GAAP net income was $35,477 or $0.27 per diluted share against adjusted non-GAAP net loss of $1,104 million or $0.02 per diluted share a year ago. EBITDA was $4.861 million against LBITDA of $97.616 million a year ago. Adjusted EBITDA was $41.006 million against adjusted LBITDA of $0.104 million a year ago. Cash provided by operating activities was $10.079 million against cash used in operating activities of $11.178 million a year ago. Non-GAAP cash provided by operating activities was $32.565 million against non-GAAP cash used in operating activities of $11.178 million a year ago. For the year, the company’s total net sales were $297.0 million, compared with $74.0 million for the full year 2013, representing 301% year over year growth. Operating loss was $8,491 million against $42,854 million a year ago. Loss before benefit for income taxes was $269,687 million against $150,126 million a year ago. Net loss was $263,603 million against $149,005 million a year ago. Net loss per basic and diluted share was $3.15 against $2.34 a year ago. Net cash provided by operating activities was $27,549 million against net cash used in operating activities was $54,287 million a year ago. Purchases of property and equipment were $3,500 million against $1,198 million a year ago. Adjusted non-GAAP net income was $92,498 million or $0.95 per diluted share against adjusted non-GAAP net loss of $36,889 million or $0.58 per diluted share a year ago. LBITDA was $192.412 million against $128.972 million a year ago. Adjusted EBITDA was $105.352 million against adjusted LBITDA of $28.254 million a year ago. Non-GAAP cash provided by operating activities was $93.185 million against non-GAAP cash used in operating activities of $54.287 million a year ago. The company revised earnings guidance for the year 2015. The company expects net sales of $450 million to $475 million and adjusted EBITDA of $170 million to $190 million against previously provided guidance of net sales of $425 million to $450 million and adjusted EBITDA of $160 million to $180 million. The company estimates an effective tax rate in the low single digits for 2015.

Horizon Pharma plc Opens New Global Corporate Headquarters in Dublin

Horizon Pharma plc announced that it has formally opened its new Global Corporate Headquarters in Dublin, located at Connaught House, Burlington Road in Dublin 4. The company plans to add sixty highly skilled jobs at its headquarter facility over the next three years.

Horizon Pharma plc Opens Chicago Office

Horizon Pharma plc announced it has opened a Chicago office. The office, which is located at 150 South Wacker Drive, will primarily house commercial, corporate analytics and business development staff.

Similar Private Companies By Industry

Company Name Region
Abbott Ireland Limited Europe
Shire Pharmaceuticals Ireland Ltd Europe
Clonmel Healthcare Limited Europe
Elan Pharma International Ltd. Europe
Bimeda Holdings PLC Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 19, 2014
Vidara Therapeutics International Public Limited Company
Private Placement
March 18, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Horizon Pharma plc, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.